DR5 antibodies and articles of manufacture containing same

Details DR5 antibodies and articles of manufacture containing same DR5 antibodies and articles of manufacture containing same

2006-01-30

2011-10-04

Saoud, Christine J (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S135100, C424S139100, C424S141100, C424S143100, C530S387100, C530S387300, C530S387900, C530S388100, C530S388220

Reexamination Certificate

active

08029783

ABSTRACT:
The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.

REFERENCES:
patent: 4342566 (1982-08-01), Theofilopoulos et al.
patent: 4419446 (1983-12-01), Howley et al.
patent: 4485045 (1984-11-01), Regen et al.
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4560655 (1985-12-01), Baker et al.
patent: 4601978 (1986-07-01), Karin et al.
patent: 4657866 (1987-04-01), Kumar et al.
patent: 4676980 (1987-06-01), Segal et al.
patent: 4736866 (1988-04-01), Leder et al.
patent: 4767704 (1988-08-01), Cleveland et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 4927762 (1990-05-01), Darfler et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5047335 (1991-09-01), Paulson et al.
patent: 5122469 (1992-06-01), Mather et al.
patent: 5278299 (1994-01-01), Wong et al.
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5510261 (1996-04-01), Goochee et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5750373 (1998-05-01), Garrard et al.
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5821333 (1998-10-01), Carter et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 6030945 (2000-02-01), Ashkenazi et al.
patent: 6072047 (2000-06-01), Rauch et al.
patent: 6113898 (2000-09-01), Anderson et al.
patent: 6252050 (2001-06-01), Ashkenazi et al.
patent: 6284236 (2001-09-01), Wiley et al.
patent: 6313269 (2001-11-01), Deen et al.
patent: 6342369 (2002-01-01), Ashkenazi et al.
patent: 6342383 (2002-01-01), Perron et al.
patent: 6433147 (2002-08-01), Ni et al.
patent: 6461823 (2002-10-01), Ni et al.
patent: 6468532 (2002-10-01), Hsei et al.
patent: 6569642 (2003-05-01), Rauch et al.
patent: 6642358 (2003-11-01), Rauch et al.
patent: 6743625 (2004-06-01), Ni et al.
patent: 6746668 (2004-06-01), Ashkenazi et al.
patent: 7115717 (2006-10-01), Mori et al.
patent: 7244429 (2007-07-01), Zhou et al.
patent: 7279160 (2007-10-01), Zhou et al.
patent: 2001/0010924 (2001-08-01), Deew et al.
patent: 2001/0023691 (2001-09-01), Sekiya
patent: 2002/0048785 (2002-04-01), Holfzman
patent: 2002/0072091 (2002-06-01), Ni et al.
patent: 2002/0098550 (2002-07-01), Ni et al.
patent: 2002/0160446 (2002-10-01), Holtzman et al.
patent: 2003/0125554 (2003-07-01), Bernard et al.
patent: 2005/0249729 (2005-11-01), Mori et al.
patent: 2007/0179086 (2007-08-01), Gliniak et al.
patent: 0003089 (1981-08-01), None
patent: 417563 (1990-08-01), None
patent: 870827 (1998-10-01), None
patent: 1 396 500 (2004-10-01), None
patent: WO 81/01145 (1981-04-01), None
patent: WO 87/00195 (1987-01-01), None
patent: WO 88/07378 (1988-10-01), None
patent: WO 90/03430 (1990-04-01), None
patent: WO 91/00360 (1991-01-01), None
patent: WO 93/06213 (1993-04-01), None
patent: WO 93/08829 (1993-05-01), None
patent: WO 94/11026 (1994-05-01), None
patent: WO 94/04690 (1994-06-01), None
patent: WO 94/29348 (1994-12-01), None
patent: WO 97/01633 (1997-01-01), None
patent: WO 97/25428 (1997-07-01), None
patent: WO 98/18921 (1998-05-01), None
patent: WO 98/25986 (1998-06-01), None
patent: WO 98/28426 (1998-07-01), None
patent: WO 98/32856 (1998-07-01), None
patent: WO 98/41629 (1998-09-01), None
patent: WO 98/46643 (1998-10-01), None
patent: WO 98/46751 (1998-10-01), None
patent: WO 98/51793 (1998-11-01), None
patent: WO 99/02653 (1999-01-01), None
patent: WO 99/09165 (1999-02-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/36535 (1999-07-01), None
patent: WO 99/37684 (1999-07-01), None
patent: WO 99/64461 (1999-12-01), None
patent: WO 00/73349 (2000-12-01), None
patent: WO 00/75191 (2000-12-01), None
patent: WO 01/00832 (2001-01-01), None
patent: WO 01/83560 (2001-11-01), None
patent: WO 02/09755 (2002-02-01), None
patent: WO 02/097033 (2002-12-01), None
patent: WO 03/054216 (2003-03-01), None
patent: WO 03/037913 (2003-05-01), None
patent: WO 03/038043 (2003-05-01), None
patent: WO 03/042367 (2003-05-01), None
patent: WO 03/066661 (2003-08-01), None
patent: WO 2004/106380 (2004-09-01), None
patent: WO 2005/100399 (2005-10-01), None
patent: WO 2007/027713 (2007-03-01), None
patent: WO 2007/128231 (2007-11-01), None
patent: WO 2008/066854 (2008-06-01), None
Wells, J.A. (1990). Additivity of mutational effects in proteins. Biochemistry. 29(37):8509-8517.
Ngo et al. (1994). Computational complexity, protein structure prediction, and the Levinthal paradox. In Merz and Le Grand (Eds.) The Protein Folding Problem and Tertiary Structure Prediction. Birkhauser:Boston, pp. 491-495.
Skolnick et al. (2000). From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology. 18:34-39.
Rudikoff et al. (1982). Single amino acid substitution altering antigen-binding specificity. Proc. Natl. Acad. Sci. USA. 79:1979-1983.
Bioscience Information Service, Philadelphia, Mar. 22, 2002, Liu W.M. et al., “Trail R2 (DR5) is a Novel, Selective Therapeutic Target for Rheumatoid Arthritis” abstract, & Faseb Journal, vol. 16, Mar. 22, 2002, p. A1047, Annual Meeting of Professional Research Scientists on Experimental biology; New Orleans, Louisiana, USA; Apr. 20-24, 2002.
Buchsbaum Donald J, et al., “Antitumor efficacy of TRA-8 Anti-DR5 Monoclonal Antibody alone or in combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model”, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, Sep. 1, 2003, pp. 3731-3741.
Griffith T.S., et al., “Functional Analysis of Trail Receptors Using Monoclonal Antibodies”, Journal of Immunology, vol. 162, Mar. 1, 1999, pp. 2597-2605.
Ichikawa K, et al., “Tunoricidal Activity of a Novel Anti-Human DR5 Monoclonal Antibody without Hepatocyte Cytotoxicity”, Nature Medicine, Nature America, New York, US, vol. 8, No. 8, Aug. 2001, pp. 954-960.
Johnson Ron et al., “Human Agonistic Anti-Trail Receptor Antibodies, HGS-ETR1 and HGS-ETR2, induce Apoptosis in Diverse Hematological Tumor Lines”, Blood, vol. 102, Nov. 16, 2003, p. 891a, & 45thAnnual Meeting of the American Society of Hematology; San Diego, Ca USa; Dec. 6-9, 2003, abstract.
Morl E. et al., “An Anti-Tumor Trail Receptor 2 Human Antibody without Hepatocyte Toxicity”, Proceedings of the Annual Meeting of the American Association for Cancer Research, New York, NY, US, vol. 44, Jul. 11, 2003, p. 1285.
Takeda et al., “Induction of Tumor-Specific T Cell Immunity by Anti-DR5 Antibody Therapy”, Journal of Experimental Medicine, Tokyo, JP, vol. 199, Feb. 16, 2004, pp. 437-448.
AgnewChem Intl. Ed. Engl., 33:183-186 (1994).
Anderson et al.,Nature, 390:175-179 (1997).
Armitage et al. Nature, 357:80-82 (1992).
Ashkenazi and Dixit,Curr. Opin. Cell Biol., 11:255-260 (2000).
Ashkenazi and Dixit,Science, 281:1305-1308 (1998).
Ashkenazi et al., J. Clin. Invest., 104:155-162 (1999).
Ashkenazi,Nature Reviews, 2:420-430 (2002).
Bodmer et al.,Nature Cell Biol., 2:241-243 (2000).
Boerner et al.,J. Immunol., 147 (1):86-95 (1991.
Boyd et al.,Mol. Immunol. 32:1311-1318 [1996].
Bradley, inTeratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152.
Brennan et al.,Science229:81 (1985).
Brodeur et al.,Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63.
Browning et al., Cell, 72:847-856 (1993).
Burton,Molec. Immunol.22:161-206 (1985).
Capel et al.,Immunomethods, 4:25-34 (1994).
Carter et al.,Bio/Technology10:163-167 (1992).
Cha et al., Immunity, 11:253-261 (1999).
Chicheportiche et al

Affiliated with

Also associated with

Rating

DR5 antibodies and articles of manufacture containing same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DR5 antibodies and articles of manufacture containing same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DR5 antibodies and articles of manufacture containing same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4267391